What is Beta Bionics?
Beta Bionics is dedicated to revolutionizing diabetes management through its innovative iLet® Bionic Pancreas System. This system employs adaptive, self-learning control algorithms, integrated with continuous glucose monitoring and pump technology, to autonomously administer insulin and/or glucagon. The goal is to mimic the body's natural glycemic control mechanisms, thereby improving health outcomes and quality of life for those living with diabetes. As a for-profit, public benefit corporation and Certified B Corporation, Beta Bionics operates with a strong social mission, aiming to enhance the lives of patients through advanced medical technology.
How much funding has Beta Bionics raised?
Beta Bionics has raised a total of $495.6M across 7 funding rounds:
Angel/Seed
$1M
Private Equity
$2.5M
Series B
$63M
Series C
$57M
Series D
$100M
Series E
$60M
Stock Offering
$212.1M
Angel/Seed (2016): $1M, investors not publicly disclosed
Private Equity (2017): $2.5M, investors not publicly disclosed
Series B (2019): $63M supported by Zealand Pharma A/S, LifeSci Venture Partners, Dexcom, RTW Investments, and ArrowMark Partners
Series C (2022): $57M featuring ArrowMark Partners, Novo Nordisk, Soleus Capital, Pura Vida Investments, LifeSci Venture Partners, Eventide Asset Management, Perceptive Advisors, Farallon, and RTW Investments
Series D (2023): $100M backed by OMEGA Funds Investment, Sands Capital, and Marshall Wace
Series E (2024): $60M with participation from Wellington Management and Eventide Asset Management
Stock Issuance/Offering (2025): $212.1M, investors not publicly disclosed
Key Investors in Beta Bionics
OMEGA Funds Investment
OMEGA Funds Investment is a regulated EU Investment Firm that provides investment services, focusing on a wide range of financial instruments and trading options, with a commitment to high standards and international compliance.
Sands Capital
Sands Capital Management is an investment firm established in 1992, managing equity mutual funds and investing in public equity markets, headquartered in Arlington, Virginia.
Marshall Wace
Marshall Wace LLP is a global alternative investment manager specializing in long/short equity, founded in 1997 and headquartered in London, United Kingdom.
What's next for Beta Bionics?
The substantial enterprise-level funding and recent strategic investment position Beta Bionics for accelerated growth and the scaling of its iLet® Bionic Pancreas System. This capital infusion is expected to fuel further research and development, clinical trials, and the eventual commercialization of their groundbreaking technology. The company's focus on autonomous glycemic control addresses a critical unmet need in diabetes care, suggesting a trajectory towards becoming a leader in the medtech sector. Future developments will likely center on regulatory approvals, market penetration, and expanding the reach of their life-changing solutions.
See full Beta Bionics company page
